Treatment of human umbilical cord-derived mesenchymal stem cells for hepatitis B virus-associated decompensated liver cirrhosis: A clinical trial

Figure 1 Study flow chart: 39 participants were enrolled and 24 were recruited. Each group includes 8 participants.

Figure 2 Kaplan-Meier analysis of 3 groups. There is no statistical difference among 3 groups (log-rank P = 0.3328).

Figure 3 Variation of liver function. ^aP < 0.05 compared with baseline values in low-dose group; ^bP < 0.05 compared with baseline values in medium-dose group; ^cP < 0.05 compared with baseline values in high-dose group; ^dP < 0.05 compared among three group in the same visit. A: Serum albumin; B: Alanine aminotransferase; C: Aspartate aminotransferase; D: Serum total bilirubin; E: Serum direct bilirubin; F: Total cholesterol. ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; T-Bil: Total bilirubin; D-Bil: Direct bilirubin; TC: Total cholesterol.

Figure 4 Variation of coagulation function. ^aP < 0.05 compared with baseline values in low-dose group; ^cP < 0.05 compared with baseline values in high-dose group. A: Prothrombin time activity; B: Antithrombin-III. PTTA: Prothrombin time activity; AT-III: Antithrombin-III.

Figure 5 Variation of general condition. ^aP < 0.05 compared with baseline values, representing low-dose group. A: Weight of participant; B: Child-Pugh score; C: Model for End-Stage Liver Disease score. MELD: Model for End-Stage Liver Disease.

Figure 6 Variation of immune system. ^aP < 0.05 compared with baseline values in low-dose group; ^cP < 0.05 compared with baseline values in high-dose group; ^dP < 0.05 compared among three group in the same visit. A: CD4+ T cell; B: CD8+ cell; C: Natural killer cell; D: Interleukin-8. NK cell: Natural killer cell; IL-8: Interleukin-8.

Figure 7 Most common adverse event. The most common 15 adverse event were displayed and the horizontal axis represents person-time, which display the frequency in each group.